Last reviewed · How we verify
Arm A: Atezolizumab and Radiotherapy — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Arm A: Atezolizumab and Radiotherapy (Arm A: Atezolizumab and Radiotherapy) — The Netherlands Cancer Institute.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Arm A: Atezolizumab and Radiotherapy TARGET | Arm A: Atezolizumab and Radiotherapy | The Netherlands Cancer Institute | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Arm A: Atezolizumab and Radiotherapy CI watch — RSS
- Arm A: Atezolizumab and Radiotherapy CI watch — Atom
- Arm A: Atezolizumab and Radiotherapy CI watch — JSON
- Arm A: Atezolizumab and Radiotherapy alone — RSS
Cite this brief
Drug Landscape (2026). Arm A: Atezolizumab and Radiotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/arm-a-atezolizumab-and-radiotherapy. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab